Member Info for Tamlin

Last updated: 08:45 22 Jun 2026 BST, First published: 07:45 22 Jun 2026 BST

https://www.proactiveinvestors.co.uk/companies/news/1094238/cellbxhealth-ceo-on-strategy-reset-and-growth-plans.html

Regardless of whether you are a cynic, more intermittent renewable energy is going to surge.

https://archive.ph/KCd7Q

Shield's licensing partner, Norgine B.V. holds the marketing authorisation and is responsible for commercialising FeRACCRU® in the European Union. Shield will receive a milestone payment of €500,000 from Norgine related to this EMA approval for the term of the agreement.

Feraccru - Approved

Feraccru is indicated for the treatment of iron deficiency in adults and adolescents aged 12 years and older.

https://www.ema.europa.eu/en/medicines/human/variation/feraccru

Https://www.lse.co.uk/rns/STX/approval-for-accrufer-in-china-expected-in-q1-2026-wegahcq2kruwm3u.html

Shield Therapeutics’ share price is up 318% in 1 year! Should I buy now?

Shield Therapeutics’ share price has more than QUADRUPLED in a year! But is it too late for investors to buy the shares? Zaven Boyrazian investigates.

Posted by

Zaven Boyrazian, CFA ❯

@ZBoyrazian

Published 12 January, 8:11 am GMT

htTps://www.fool.co.uk/2026/01/12/the-shield-therapeutics-share-price-is-up-318-in-1-year-should-i-buy-now/

Https://www.fool.co.uk/2025/12/20/prediction-these-near-penny-stocks-could-be-among-2026s-big-winners/

Https://www.investing.com/news/analyst-ratings/stifel-upgrades-shield-therapeutics-stock-rating-to-buy-on-accrufer-growth-93CH-4271979

Stifel upgrades Shield Therapeutics stock rating to Buy on Accrufer growth

Investing.com - Stifel has upgraded Shield Therapeutics PLC (STX:LN) from Hold to Buy and raised its price target to GBP0.10 from GBP0.03, citing improved commercial execution and financial stability.

The upgrade follows consistent growth in sales of Shield’s iron deficiency treatment Accrufer in the U.S. market, which has addressed one of Stifel’s previous concerns about volatile commercial performance.

Shield has strengthened its financial position through effective expense control and the implementation of a working capital facility, according to Stifel’s analysis. Recent equity raises have also provided additional financial headroom for the company.

Stifel now believes Shield’s target of reaching cash flow break-even by the end of 2025 is achievable, marking a significant improvement in the firm’s outlook for the pharmaceutical company.

Despite the upgrade, Stifel characterizes Shield Therapeutics as a "high-risk/high-reward proposition" within its coverage universe, indicating that while the company’s prospects have improved, investors should remain aware of potential volatility.